Correlation between ARHGAP15 immunoreactivity and breast-cancer-specific survival is summarized in Figure 2B, and ARHGAP15 immunoreactivity was significantly associated with improved clinical outcome (p = 0.032). Here, ARHGAP15 is linked to breast carcinoma.